Adherence and persistence to tafamidis treatment among Medicare beneficiaries in the presence of a patient assistance program.

Haechung Chung¹, Cera Cantu², Cindi Pankratova³, Jason Kemner³, Jose Alvir³, Sapna Prasad², Yong Chen³

¹Pfizer Inc, New York, NY, USA. Haechung.Chung@pfizer.com.

²Clarify Health Solutions, New York, NY, USA.

³Pfizer Inc, New York, NY, USA.

PubMed PMC DOI PDF

Abstract

Tafamidis is the only disease-modifying therapy approved to treat patients in the United States with transthyretin amyloid cardiomyopathy (ATTR-CM), which most commonly affects patients aged ≥ 65 years. The manufacturer operates a patient assistance program (PAP) to support access to tafamidis. This study conducted Privacy Preserving Record Linking (PPRL) using Datavant tokens to match patients ac…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.